19th Annual Infectious Disease Board Review Course
16th International Symposium on Staphylococci and Staphylococcal Infections (ISSSI)
HIV & Liver Disease 2014
Find Practice Guidelines
The Infectious Diseases Society of America (IDSA) represents physicians, scientists and other health care professionals who specialize in infectious diseases. IDSA’s purpose is to improve the health of individuals, communities, and society by promoting excellence in patient care, education, research, public health, and prevention relating to infectious diseases.
Take Three Minutes to Support Antibiotic Development
Urge Congress to help speed patient access to the most urgently needed new antibacterial drugs.
IDSA Members Call on Congress to Advance LPAD Pathway
IDSA members answered a request from the House Energy and Commerce Committee on proposals to spur drug research and development.
The STAAR Act was reintroduced by Sen. Sherrod Brown this week. The bill, championed by IDSA, provides stronger federal leadership to coordinate activities that address resistance and strengthen accountability.
IDSA Applauds President’s Commitment to Combatting Antibiotic Resistance in FY 2015 Budget, Dismayed by Related Reductions
President Obama’s Fiscal Year 2015 budget includes a request to more than double funding for the CDC to combat antibiotic resistance, in addition to requests to fund efforts to track, prevent and control antibiotic resistance in the U.S. and around the world.
IDSA Applauds State of the Union Pledge on Drug Resistance
The Society reiterated its support for the Antibiotic Development to Advance Patient Treatment Act and the Strategies to Address Antimicrobial Resistance Act.
ADAPT Act Introduced to Establish New Drug Approval Pathway
IDSA applauds the bipartisan introduction of legislation to establish a new limited-population antibacterial and antifungal drug approval pathway.
IDSA Seeks Obama Admin Support for AMR Legislation
A letter sent to President Obama asks for support for current bills addressing antimicrobial resistance. Proposals include the LPAD Pathway, tax credits for research and development of drugs and diagnostics, STAAR Act, and federal funding.
Capitol Hill Briefing on Antibiotic Resistance Threats to the U.S.
IDSA, CDC, and Pew Charitable Trusts will hold a briefing on the new report from CDC on antibiotic resistant threats to the US.
1 of 8
UPDATED: Guidelines for Evaluation of US Patients Suspected of Having Ebola Virus Disease
CDC Alert: Updated 8/11/2014
Cubist Pharmaceuticals Issues Voluntary U.S. Recall Of Certain Lots Of CUBICIN
FDA approves Orbactiv to treat skin infections
CDC Recommendations for Hospitalizated Patients with Ebola
>> Read More
A new CID study suggests antivirals were underprescribed for outpatients at high risk for flu complications, while antibiotics were overprescribed.
IDSA welcomes today’s news about the upcoming report on
Antimicrobial Resistance from the President’s Council of Advisors on Science
and Technology. (07/11/2014)
In this issue:
President's MessageNew Guideline on SSTI21st Century Cures InitiativeCountdown to IDWeek 2014IDSA Journal Club
In this issue:
>> Read more
IDSA releases updated skin and soft tissue (SSTI) guideline to help physicians diagnose, establish source, cause, and severity, and properly treat SSTIs.
>> Read MoreIn this issue:•President's Message•Call for Volunteers•Antimicrobial Resistance Efforts•IDWeek 2014 Registration•IDSA Journal Club
2014 IDSA Call for Committee Volunteers
>>Read more Using frozen stool from unrelated donors for fecal microbiota transplantation (FMT) was effective in a new pilot study in Clinical Infectious Diseases.
1 of 7
1300 Wilson Boulevard Suite 300 Arlington, VA 22209 | Phone: (703) 299-0200 | Fax: (703) 299-0204
| HIVMA | Contact Us
© Copyright IDSA 2014 Infectious Diseases Society of America